Health Care & Life Sciences » Biotechnology | Sangamo BioSciences Inc.

Sangamo BioSciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
93,133.00
179,282.00
209,000.00
142,535.00
243,308.00
400,133
Total Accounts Receivable
3,493.00
10,791.00
2,828.00
5,196.00
3,583.00
5,048
Other Current Assets
648.00
806.00
754.00
1,849.00
1,506.00
5,340
Total Current Assets
97,274.00
190,879.00
212,582.00
149,580.00
248,397.00
410,521
Net Property, Plant & Equipment
1,406.00
1,479.00
2,916.00
6,557.00
31,066.00
78,723
Total Investments and Advances
38,663.00
47,260.00
-
-
1,012.00
3,500
Intangible Assets
3,455.00
3,455.00
1,585.00
1,585.00
1,585.00
94,910
Other Assets
40.00
139.00
152.00
169.00
4,681.00
2,741
Total Assets
140,838.00
243,212.00
217,235.00
157,891.00
286,741.00
590,395
Accounts Payable
3,022.00
5,525.00
3,905.00
2,580.00
16.00
Other Current Liabilities
7,109.00
15,357.00
16,192.00
10,711.00
44,843.00
Total Current Liabilities
10,131.00
20,882.00
20,097.00
13,291.00
44,859.00
Long-Term Debt
-
-
-
3,945.00
24,738.00
Provision for Risks & Charges
1,570.00
1,800.00
-
-
-
Deferred Taxes
748.00
748.00
-
-
-
Other Liabilities
6,679.00
13,149.00
4,699.00
4,460.00
29,244.00
Total Liabilities
19,128.00
36,579.00
24,796.00
21,696.00
98,841.00
Common Equity (Total)
121,710.00
206,633.00
192,439.00
136,195.00
187,900.00
Total Shareholders' Equity
121,710.00
206,633.00
192,439.00
136,195.00
187,900.00
Total Equity
121,710.00
206,633.00
192,439.00
136,195.00
187,900.00
Liabilities & Shareholders' Equity
140,838.00
243,212.00
217,235.00
157,891.00
286,741.00

About Sangamo BioSciences

View Profile
Address
Point Richmond Tech Center II
Richmond California 94804
United States
Employees -
Website http://www.sangamo.com
Updated 07/08/2019
Sangamo Therapeutics, Inc. researches and develops transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O.